Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16.
Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16.
复制标题
I-125 近距离放射治疗中型脉络膜黑色素瘤的眼部黑色素瘤协作研究 (COMS) 随机试验。
DOI：
10.1016/s0161-6420(00)00526-1
复制
发表时间：
2001
期刊：
影响因子：
13.7
通讯作者：
CollaborativeOcularMelanomaStudyGroup
中科院分区：
文献类型：
--
作者：
Melia,BM;Abramson,DH;Albert,DM;Boldt,HC;Earle,JD;Hanson,WF;Montague,P;Moy,CS;Schachat,AP;Simpson,ER;Straatsma,BR;Vine,AK;Weingeist,TA;CollaborativeOcularMelanomaStudyGroup
目的报告碘125 （I(125)）近距离放射治疗中等脉络膜黑色素瘤后3年的视力，并在一组接受治疗和前瞻性观察的患者中确定与治疗后视力相关的重要基线和治疗因素，这是一项大型随机临床试验的一部分。设计
ObjectiveTo report visual acuity during the first three years after iodine 125 (I (125)) brachytherapy for medium-sized choroidal melanoma and to identify important baseline and treatment factors associated with posttreatment visual acuity in a group of patients who were treated and observed prospectively as part of a large, randomized clinical trial.Design